Citations (75)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Yongliang Fang, Thach H. Chu, Margaret E. Ackerman & Karl E. Griswold. (2017) Going native: Direct high throughput screening of secreted full-length IgG antibodies against cell membrane proteins. mAbs 9:8, pages 1253-1261.
Read now
Read now
Héctor Vázquez-Becerra, Enrique Pérez-Cárdenas, Saé Muñiz-Hernández, Vanessa Izquierdo-Sánchez & Luis Alberto Medina. (2017) Characterization and in vitro evaluation of nimotuzumab conjugated with cisplatin-loaded liposomes. Journal of Liposome Research 27:4, pages 274-282.
Read now
Read now
Assuntina G Sacco & Francis P Worden. (2016) Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. OncoTargets and Therapy 9, pages 1927-1943.
Read now
Read now
Hai Liu, Weifang Yang, Huaping Gao, Tingting Jiang, Bengxin Gu, Qinghua Dong, Wenhong Xu, Shixiu Wu & Xiaonan Sun. (2015) Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair. OncoTargets and Therapy 8, pages 509-518.
Read now
Read now
Lucely Cetina, Tania Crombet, Roberto Jiménez-Lima, Sergio Zapata, Mayra Ramos, Sandra Avila, Jaime Coronel, Eduardo Charco, Rafael Bojalil, Horacio Astudillo, Blanca Bazán & Alfonso Dueñas-González. (2015) A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biology & Therapy 16:5, pages 684-689.
Read now
Read now
K Govind Babu, Kumar Prabhash, Ashok K Vaid, Bhawna Sirohi, Ravi B Diwakar, Raghunadha Rao, Madhuchanda Kar, Hemant Malhotra, Shona Nag, Chanchal Goswami, Vinod Raina & Ravi Mohan. (2014) Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. OncoTargets and Therapy 7, pages 1051-1060.
Read now
Read now
Bénédicte FAUVEL & Aziz Yasri. (2014) Antibodies directed against receptor tyrosine kinases. mAbs 6:4, pages 838-851.
Read now
Read now
Mital Patel, Michael A Vogelbaum, Gene H Barnett, Rakesh Jalali & Manmeet S Ahluwalia. (2012) Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opinion on Investigational Drugs 21:9, pages 1247-1266.
Read now
Read now
Masayuki Takeda, Isamu Okamoto, Yasumasa Nishimura & Kazuhiko Nakagawa. (2011) Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. Lung Cancer: Targets and Therapy 2, pages 59-67.
Read now
Read now
Maura Massimino, Udo Bode, Veronica Biassoni & Gudrun Fleischhack. (2011) Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opinion on Biological Therapy 11:2, pages 247-256.
Read now
Read now
William Boland & Gwyn Bebb. (2010) The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics: Targets and Therapy 4, pages 289-298.
Read now
Read now
Articles from other publishers (64)
Mohammad Anisuzzman, Varsha Komalla, Mariam Abdulaziz M. Tarkistani & Veysel Kayser. (2023) Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers. Journal of Functional Biomaterials 14:8, pages 407.
Crossref
Crossref
Masahiro Yasunaga. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
31
.
Sousa Javan Nikkhah, Pierre A. Cazade, Jennifer J. McManus & Damien Thompson. (2022) Design Rules for Antibody Delivery by Self-Assembled Block-Copolyelectrolyte Nanocapsules. Macromolecules 55:7, pages 2383-2397.
Crossref
Crossref
Alert J, Chon I, Valdes J, Ropero R, Perez M, Garcia D D, Forteza M & Avila J. (2021) Very long-term of survival, 5 years and more in diffuse intrinsic pontine brainstem gliomas in children and adolescents treated with Radiotherapy and Nimotuzumab. International Journal of Radiology & Radiation Therapy 8:2, pages 86-90.
Crossref
Crossref
Amir-Hassan Zarnani, Davood Jafari, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2021. Cancer Immunology. Cancer Immunology
273
312
.
Xishan Chen, Renba Liang & Xiaodong Zhu. (2020) Anti-EGFR therapies in nasopharyngeal carcinoma. Biomedicine & Pharmacotherapy 131, pages 110649.
Crossref
Crossref
A. A. Rosenkranz & T. A. Slastnikova. (2020) Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery. Biochemistry (Moscow) 85:9, pages 967-993.
Crossref
Crossref
Carmen Viada, Aliz M. Vega, Mayte Robaina, Aliuska Frías, Mabel Álvarez, Yanela Santiesteban, Yuliannis Santiesteban, Lázara García, Braulio Mestre, Marta xxx Osorio, Leslie Pérez, Amparo Macias, Tania Crombet & Mayra Ramos. (2020) Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. Bionatura 5:1, pages 1056-1062.
Crossref
Crossref
Sai-xi Bai, Ruo-rong Zhang, Wang-hua Chen, Hong-min Dong, Gang Wang, Xiao-kai Li & Wenling Wang. (2020) Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis. Journal of International Medical Research 48:1, pages 030006051989585.
Crossref
Crossref
Athina-Maria Aloizou, Georgia Pateraki, Vasileios Siokas, Alexios-Fotios A. Mentis, Ioannis Liampas, George Lazopoulos, Leda Kovatsi, Panayiotis D. Mitsias, Dimitrios P. Bogdanos, Konstantinos Paterakis & Efthimios Dardiotis. (2020) The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?. Toxicology Reports 7, pages 1514-1530.
Crossref
Crossref
Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu & Chung-Tsen Hsueh. (2019) Targeted and novel therapy in advanced gastric cancer. Experimental Hematology & Oncology 8:1.
Crossref
Crossref
Sidi Li, Luyang Chen, Kai Huang, Ning Chen, Qi Zhan, Kaikai Yi, Hongzhao Qi, Chaoyong Liu, Yanli Tan, Xin Hou, Yunfeng Lu, Jin Zhao, Xubo Yuan & Chunsheng Kang. (2019) Tumor Microenvironment‐Tailored Weakly Cell‐Interacted Extracellular Delivery Platform Enables Precise Antibody Release and Function. Advanced Functional Materials 29:43.
Crossref
Crossref
Jiancheng Li, Linghua Wang, Zidan Qiu & Ying Su. (2019) Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line. Oncology Letters.
Crossref
Crossref
Jing Li & Hengxiu Yan. (2018) Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemotherapy and Pharmacology 82:4, pages 571-583.
Crossref
Crossref
Jose Alert, Ivon Chon, Jose Valdes, Ramon Ropero, Jesus Reno, Migdalia Perez, Mariuska Forteza & Debora Garcia. (2018) Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiatherapy and Nimotuzumab. International Journal of Radiology & Radiation Therapy 5:4.
Crossref
Crossref
Jose Alert, Ivon Chon, Jose Valdes, Ramon Ropero, Jesus Reno, Migdalia Perez, Mariuska Forteza & Debora Garcia. (2018) Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiotherapy and Nimotuzumab. International Journal of Radiology & Radiation Therapy 5:4.
Crossref
Crossref
Jing Li & Jing Xie. (2018) Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials. Japanese Journal of Clinical Oncology 48:8, pages 718-727.
Crossref
Crossref
Zaima Mazorra, Lisset Chao, Anabel Lavastida, Belinda Sanchez, Mayra Ramos, Normando Iznaga & Tania Crombet. (2018) Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology 45:1-2, pages 18-26.
Crossref
Crossref
S Hermanto, M Yusuf, A Mutalib & S Hudiyono. (2017)
Molecular dynamic simulation of Trastuzumab F(ab’)
2
structure in corporation with HER2 as a theranostic agent of breast cancer
. Journal of Physics: Conference Series 835, pages 012005.
Crossref
Crossref
Arathi Kizhedath, Simon Wilkinson & Jarka Glassey. (2016) Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope. Archives of Toxicology 91:4, pages 1595-1612.
Crossref
Crossref
Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, Myung-Ju Ahn, Dong-Wan Kim, Inkyung Jung, Ki Hyeong Lee, Joo-Hang Kim, Dae Ho Lee, Sang-We Kim & Byoung Chul Cho. (2016) A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget 8:9, pages 15943-15951.
Crossref
Crossref
Matthew Zibelman & Ranee Mehra. (2016) Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 39:4, pages 396-406.
Crossref
Crossref
J. Jia, Y. Cui, M. Lu, X. Wang, Jie Li, Jian Li, Y. Li, X. Zhang, J. Gao, J. Zhou, Z. Lu, J. Gong, J. Yu, Z. Sun, C. Liu, L. Shen & X. Zhang. (2015) The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. Clinical and Translational Oncology 18:6, pages 592-598.
Crossref
Crossref
Shuping Xu, Mayra Ramos-Suzarte, Xianhong Bai & Binghe Xu. (2016) Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget 7:22, pages 33391-33407.
Crossref
Crossref
Ji Yun Lee, Jong-Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Bo Mi Ku, Jiae Koh, Yeon-Hee Bae, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park & Myung-Ju Ahn. (2016) A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research 22:9, pages 2139-2145.
Crossref
Crossref
Yusuke Nitta, Saki Shimizu, Yukiko Shishido‐Hara, Kaori Suzuki, Yoshiaki Shiokawa & Motoo Nagane. (2016)
Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant
EGFR
in vivo
. Cancer Medicine 5:3, pages 486-499.
Crossref
Crossref
Tsz-Lun Yeung, Cecilia Leung, Fuhai Li, Stephen Wong & Samuel Mok. (2016) Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules 6:1, pages 3.
Crossref
Crossref
Martin Gasser & Ana Maria Waaga-Gasser. 2016. Protein Targeting Compounds. Protein Targeting Compounds
95
120
.
Dawn Q Chong, Xin Y Toh, Ivy AW Ho, Kian C Sia, Jennifer P Newman, Yulyana Yulyana, Wai-Hoe Ng, Siang H Lai, Mac MF Ho, Nivedh Dinesh, Chee K Tham & Paula YP Lam. (2015) Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer 15:1.
Crossref
Crossref
Daxing Liu & Debra T. Auguste. (2015) Cancer targeted therapeutics: From molecules to drug delivery vehicles. Journal of Controlled Release 219, pages 632-643.
Crossref
Crossref
Mythili Kameswaran, Grace Samuel, Haladhar Dev Sarma, Swamirao N. Shinde, Ashutosh Dash & Meera Venkatesh. (2015) 131 I-Nimotuzumab – A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR. Applied Radiation and Isotopes 102, pages 98-102.
Crossref
Crossref
Hongxiang Wang, Tao Xu, Ying Jiang, Hanchong Xu, Yong Yan, Da Fu & Juxiang Chen. (2015) The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas. Neoplasia 17:3, pages 239-255.
Crossref
Crossref
B. Ravi Shankar, Poojar Kiran, B. V. Madhavi & E. Vijay. (2015) Concurrent Nimotuzumab with Radiation Therapy in Locally Advanced Cancers of Oropharynx and Hypopharynx: A Review of 6 Cases. Journal of Cancer Therapy 06:04, pages 390-398.
Crossref
Crossref
Amir-Hassan Zarnani, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2015. Cancer Immunology. Cancer Immunology
293
328
.
Martin Gasser & Ana Maria Waaga-Gasser. 2015. Protein Targeting Compounds. Protein Targeting Compounds
95
120
.
Marlène Soussan-Dahan, Maryse Lapeyre-Mestre, Emmanuelle Bondon-Guitton, Jean-Pierre Delord & Fabien Despas. (2014) Effets indésirables cutanés sous cetuximab en conditions réelles d’utilisation : indicateur d’efficacité pour les cancers colorectaux métastatiques et les cancers des voies aérodigestives supérieures ?. Therapies 69:6, pages 499-507.
Crossref
Crossref
Dan Su, Shun-Chang Jiao, Li-Jie Wang, Wei-Wei Shi, Yan-Yan Long, Juan Li & Li Bai. (2013) Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumor Biology 35:3, pages 2313-2318.
Crossref
Crossref
Kai-liang Zhang, Lei Han, Lu-yue Chen, Zhen-dong Shi, Ming Yang, Yu Ren, Ling-chao Chen, Jun-xia Zhang, Pei-yu Pu & Chun-sheng Kang. (2014) Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. Cancer Letters 342:1, pages 139-149.
Crossref
Crossref
A. Mortlock, K. Foote, J. Kettle & B. Aquila. 2014. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Maria Teresa Solomón, Julio César Selva, Javier Figueredo, José Vaquer, Carolina Toledo, Nelson Quintanal, Silvia Salva, Rafael Domíngez, José Alert, Jorge Juan Marinello, Mauricio Catalá, Martha González Griego, Juan Antonio Martell, Patricia Lorenzo Luaces, Javier Ballesteros, Niurys de-Castro, Ferdinand Bach & Tania Crombet. (2013) Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 13:1.
Crossref
Crossref
Kobra Omidfar, Fatemeh Sadat Amjad Zanjani, Arghavan Golbaz Hagh, Maedeh Darziani Azizi, Seyed Javad Rasouli & Susan Kashanian. (2013) Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody. Molecular Biology Reports 40:12, pages 6737-6745.
Crossref
Crossref
Feras Oskan, Claus Belka & Farkhad Manapov. (2013) Is Cetuximab-Induced Rash Conclusion Really a Remnant of the Skin Erythema Dose?. International Journal of Radiation Oncology*Biology*Physics 87:3, pages 462-463.
Crossref
Crossref
Wataru Okamoto, Takayuki Yoshino, Toshiaki Takahashi, Isamu Okamoto, Shinya Ueda, Asuka Tsuya, Narikazu Boku, Kazuto Nishio, Masahiro Fukuoka, Nobuyuki Yamamoto & Kazuhiko Nakagawa. (2013) A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 72:5, pages 1063-1071.
Crossref
Crossref
Se Hyun Kim, Hyo Sup Shim, Jaeho Cho, Jae Heon Jeong, Sun Mi Kim, Yun Kyoung Hong, Ji Hee Sung, Sang-Jun Ha, Hye Ryun Kim, Hyun Chang, Joo Hang Kim, Crombet Tania & Byoung Chul Cho. (2013) A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 79:3, pages 270-275.
Crossref
Crossref
Charles E. Rengifo, Rancés Blanco, Damián Blanco, Mercedes Cedeño, Milagros Frómeta & Enrique Rengifo Calzado. (2013) Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy. Journal of Biomarkers 2013, pages 1-9.
Crossref
Crossref
John G. Elvin, Ruairidh G. Couston & Christopher F. van der Walle. (2013) Therapeutic antibodies: Market considerations, disease targets and bioprocessing. International Journal of Pharmaceutics 440:1, pages 83-98.
Crossref
Crossref
Denis R. Beckford Vera, Sebastian Eigner, Katerina Eigner Henke, Rene Leyva Montaña, Frantisek Melichar & Milos Beran. 2013. Theranostics, Gallium-68, and Other Radionuclides. Theranostics, Gallium-68, and Other Radionuclides
301
317
.
Roshan James, Siddharth Vishwakarma, Indira V. Chivukula, Chetana Basavaraj, Ramakrishnan Melarkode, Enrique Montero & Pradip Nair. (2012)
EGFR
targeting monoclonal antibody combines with an
mTOR
inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
. Cancer Medicine 1:2, pages 114-127.
Crossref
Crossref
K. Bouzid, N. Bedairia & M. Marty. (2012) Anticorps monoclonaux thérapeutiques en cancérologie. Pathologie Biologie 60:4, pages 223-228.
Crossref
Crossref
Kobra OmidfarZaynab Shirvani. (2012) Single Domain Antibodies: A New Concept for Epidermal Growth Factor Receptor and EGFRvIII Targeting. DNA and Cell Biology 31:6, pages 1015-1026.
Crossref
Crossref
Dirk Strumberg, Beate Schultheis, M. E. Scheulen, R. A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler & K. Mross. (2010) Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Investigational New Drugs 30:3, pages 1138-1143.
Crossref
Crossref
Andrew M. Scott, Jedd D. Wolchok & Lloyd J. Old. (2012) Antibody therapy of cancer. Nature Reviews Cancer 12:4, pages 278-287.
Crossref
Crossref
Arlhee Diaz, Rances Blanco, Margit Lemm, Iduna Fichtner, Kalet Leon & Enrique Montero. (2012) Preclinical Efficacy of Nimotuzumab, an Anti-Egfr Monoclonal Antibody as a Single Agent Therapy in Human GBM u87mg Xenografts. Journal of Cancer Therapy 03:04, pages 245-255.
Crossref
Crossref
Denis R. Beckford Vera, Sebastian Eigner, Katerina Eigner Henke, Ondrej Lebeda, Frantisek Melichar & Milos Beran. (2012) Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nuclear Medicine and Biology 39:1, pages 3-13.
Crossref
Crossref
Arlhee Diaz & Kalet Leon. (2011) Therapeutic Approaches to Target Cancer Stem Cells. Cancers 3:3, pages 3331-3352.
Crossref
Crossref
Stanislas Blein & Sam Hou. (2011) Therapeutic Monoclonal Antibodies: Current Perspectives and Applications for the Treatment of Head and Neck Cancer. International Journal of Head and Neck Surgery 2:2, pages 87-94.
Crossref
Crossref
N. Ledón, A. Casacó, E. Casanova & I. Beausoleil. (2011) Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models. Placenta 32:7, pages 531-534.
Crossref
Crossref
Ariel Talavera, Jenny Mackenzie, Greta Garrido, Rosmarie Friemann, Alejandro López-Requena, Ernesto Moreno & Ute Krengel. (2011) Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site. Molecular Immunology 48:12-13, pages 1578-1585.
Crossref
Crossref
Rolando Perez, Ernesto Moreno, Greta Garrido & Tania Crombet. (2011) EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers 3:2, pages 2014-2031.
Crossref
Crossref
Gwyn Bebb, Colum Smith, Stewart Rorke, William Boland, Leonardo Nicacio, Ryan Sukhoo & Anthony Brade. (2010) Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemotherapy and Pharmacology 67:4, pages 837-845.
Crossref
Crossref
Agustin Lage & Tania Crombet. (2011) Control of Advanced Cancer: The Road to Chronicity. International Journal of Environmental Research and Public Health 8:3, pages 683-697.
Crossref
Crossref
Mark D. Savellano, Nicci Owusu-Brackett, Ji Son, Thierri Callier & Dagmar Högemann Savellano. (2010) Development of an ErbB-overexpressing A-431 Optical Reporting Tumor Xenograft Model to Assess Targeted Photodynamic Therapy Regimens. Photochemistry and Photobiology 86:6, pages 1379-1389.
Crossref
Crossref
Federico Rojo, Elías Gracias, Nadia Villena, Teresa Cruz, Josep Maria Corominas, Irene Corradino, Mercedes Cedeño, Clara Campas, Marta Osorio, Normando Iznaga, Beatriz Bellosillo, Ana Rovira, Silvia Marsoni, Pere Gascon, Sergio Serrano, Cristiana Sessa, Tania Crombet & Joan Albanell. (2010) Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. Clinical Cancer Research 16:8, pages 2474-2482.
Crossref
Crossref
Frédéric Hollande, Julie Pannequin & Dominique Joubert. (2010) The long road to colorectal cancer therapy: Searching for the right signals. Drug Resistance Updates 13:1-2, pages 44-56.
Crossref
Crossref